Alterity Therapeutics Ltd - Asset Resilience Ratio
Alterity Therapeutics Ltd (ATH) has an Asset Resilience Ratio of 88.34% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Alterity Therapeutics Ltd (ATH) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Alterity Therapeutics Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Alterity Therapeutics Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Alterity Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Alterity Therapeutics Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$33.16 Million | 72.04% |
| Short-term Investments | AU$7.50 Million | 16.3% |
| Total Liquid Assets | AU$40.66 Million | 88.34% |
Asset Resilience Insights
- Very High Liquidity: Alterity Therapeutics Ltd maintains exceptional liquid asset reserves at 88.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Alterity Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Alterity Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Alterity Therapeutics Ltd (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Alterity Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 16.30% | AU$7.50 Million ≈ $5.31 Million |
AU$46.03 Million ≈ $32.57 Million |
-- |
| 2024-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$19.22 Million ≈ $13.60 Million |
-- |
| 2022-06-30 | 84.15% | AU$34.81 Million ≈ $24.63 Million |
AU$41.36 Million ≈ $29.27 Million |
+0.44pp |
| 2021-06-30 | 83.71% | AU$28.12 Million ≈ $19.89 Million |
AU$33.59 Million ≈ $23.76 Million |
+82.26pp |
| 2020-06-30 | 1.45% | AU$192.71K ≈ $136.35K |
AU$13.30 Million ≈ $9.41 Million |
-70.88pp |
| 2019-06-30 | 72.33% | AU$14.40 Million ≈ $10.19 Million |
AU$19.91 Million ≈ $14.09 Million |
-9.09pp |
| 2018-06-30 | 81.41% | AU$15.25 Million ≈ $10.79 Million |
AU$18.73 Million ≈ $13.25 Million |
-5.33pp |
| 2017-06-30 | 86.74% | AU$21.93 Million ≈ $15.52 Million |
AU$25.28 Million ≈ $17.89 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$33.73 Million ≈ $23.86 Million |
-- |
| 2015-06-30 | 0.36% | AU$152.60K ≈ $107.98K |
AU$41.83 Million ≈ $29.60 Million |
-0.23pp |
| 2007-06-30 | 0.59% | AU$45.63K ≈ $32.28K |
AU$7.72 Million ≈ $5.46 Million |
+0.18pp |
| 2006-06-30 | 0.41% | AU$42.40K ≈ $30.00K |
AU$10.43 Million ≈ $7.38 Million |
-- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-… Read more